Mohammad AskarPublic working copy · medical review pending

Age-related macular degeneration · 184

Age-related macular degeneration: stage, activity and next step

Separate early/intermediate AMD, atrophy and active neovascular disease before discussing prevention or injections.

Public working copy · medical review pending. Source, translation and medical checks remain open. Read the limitations in the text and references. These educational materials do not replace individual medical assessment. Published: 2026-11-18T19:45:52+01:00. Internal project references lead to this notice. They are not publicly accessible primary sources; the source limitations remain stated in the text.

Stage and activity guide management. Supplements are for selected risk groups; anti-VEGF treats active neovascular disease, and slowing atrophy growth is not the same as improving vision.

Terminology and draft status

Terminology review is not complete. No new WHO UMD entry verification is claimed for this copy; pending entries and limits are recorded in terminology.md.

01Start with stage and clinical urgency

AMD is a major cause of irreversible central visual impairment in older adults, not universally the leading cause of all blindness worldwide above age50. The export’s one-third clinic workload is a local unverified estimate. Atrophy usually progresses gradually; neovascular disease can cause rapid exudation or bleeding, and both processes can coexist. 1

Use the Beckman clinical classification: medium drusen63–<125µm without AMD-related pigment abnormalities are early AMD; large drusen≥125µm and/or relevant pigment abnormalities define intermediate AMD. Late AMD includes neovascular disease and geographic atrophy (GA). Small drusen alone are not automatically AMD. Stage each eye and distinguish drusen below the RPE from intraretinal hard exudates and subretinal drusenoid deposits. 1 2

02Read OCT as an optical image of anatomy

The photoreceptor–RPE–Bruch membrane complex is central to AMD. On OCT identify the foveal contour, outer retinal bands including the ellipsoid zone and the RPE/Bruch complex; the historical IS/OS term is not a literal histological boundary. The retina’s10 anatomical layers do not correspond to10 independently resolved OCT bands. Signal quality, segmentation and the entire scan matter before interpreting a bright or missing line. 1

The choroid is highly vascular; its thickness and vascular pattern can suggest a pachychoroid differential, but thickness alone does not diagnose or exclude AMD. RPE dysfunction, lipid/protein deposits, complement, ageing, genetic susceptibility and smoking interact. Lipofuscin and basal laminar deposits are different structures; a simple obligatory RPE atrophy→hypoxia→VEGF chain cannot explain every neovascular lesion. 1

03Separate risk reduction from treatment of established disease

Age and family history inform risk; smoking is an important modifiable factor. Discuss smoking cessation, a balanced diet and general vascular health. The quoted55% familial correlation is not an individual inheritance probability, and low lutein/zeaxanthin intake is not proof that deficiency alone causes AMD. The September2026 German S1 risk/prevention guideline is identified; its exact full recommendations still require inspection before claiming detailed concordance. 1

Consider an AREDS2-type formulation in the appropriate intermediate/high-risk setting, not for primary prevention in every healthy eye or every early AMD. The original roughly20% statement concerns an incompletely specified endpoint; NEI describes about25% relative reduction in advanced AMD over5years with the original AREDS formulation. This is not a25-percentage-point benefit or restoration of lost vision. Lutein/zeaxanthin replace beta-carotene in AREDS2-type formulations; current/former smokers should avoid beta-carotene-containing AREDS products. Check zinc/copper, vitamins C/E, interactions and the actual product with the clinician. 1 3

04Distinguish activity from atrophy and other fluid

Describe intraretinal fluid (IRF), subretinal fluid (SRF), pigment epithelial detachment (PED), blood and outer retinal integrity. IRF is often associated with worse visual outcomes than isolated SRF, but this is prognostic association, not a rule that every SRF pocket is harmless or that a dry scan ensures good function. Nonexudative degenerative cavities and tubulation can mimic active fluid. 1

GA is not defined universally by RPE loss above175µm, the export’s historical threshold. CAM cRORA requires the specified OCT combination of RPE attenuation/disruption and choroidal hypertransmission over≥250µm with overlying photoreceptor degeneration and exclusion of RPE tear; iRORA denotes incomplete criteria. FAF supports extent/follow-up but low signal can also be blocked, and a bright border is not specific proof of metabolic failure. Use OCT and fundus/FAF together. 1 4

Type1 macular neovascularisation (MNV/CNV) lies below RPE, type2 above RPE in the subretinal space and type3 is an intraretinal neovascular complex, historically RAP. These anatomical types do not map perfectly onto occult/classic FA leakage. Reticular pseudodrusen lie above RPE and mark increased progression risk, not a certain future outcome. OCT-A depicts flow without dye but does not show leakage; FA and selected ICGA answer complementary questions. 1

05Read atrophy treatment by endpoint and jurisdiction

Pegcetacoplan (Syfovre, C3) and avacincaptad pegol (Izervay, C5) entered U.S. GA care in2023; this does not mean availability or authorisation everywhere. The original20–25% slowing summarises selected anatomical outcomes across different trials, arms and time points, not guaranteed visual improvement or a universal effect. Discuss injection burden, conversion to neovascular disease and ocular inflammation alongside possible lesion-growth reduction. Full trial-specific effects and current local labels remain separate source tasks. 1

EMA’s re-examination confirmed a negative Syfovre opinion because the anatomical effect had not established a favourable clinical benefit–risk balance. Thus the export’s “available since2023” cannot be used as a German treatment standard. Check the current jurisdiction-specific decision for each product; a past refusal is not evidence about a different medicine. 1 5

Photobiomodulation (PBM, Valeda) is not established routine AMD care. The July2025 DOG/BVA/RG statement recommends use only in clinical trials because efficacy and safety remain uncertain. Its9sessions over3–5weeks describe a treatment course, not proof that mitochondrial activation improves vision. Regulatory clearance/CE marking and a recommendation for routine clinical benefit are different claims. 1 6

06Treat active neovascular disease and monitor response

Anti-VEGF is the main treatment for active nAMD. Ranibizumab (Lucentis), aflibercept (Eylea, including8mg) and faricimab (Vabysmo, also targeting Ang-2) differ in study populations, schedules and labels; bevacizumab (Avastin) is used off-label in this setting. Treat-and-extend (T&E) adjusts a proactive interval to activity; PRN treats when indicated but still requires scheduled monitoring. Neither approach guarantees fewer visits or freedom from recurrence. 1

Injection safety requires a trained sterile pathway, ocular surface antisepsis and site selection for lens status and anatomy. The original5% povidone-iodine and3.5–4mm from limbus are common procedural parameters, not a complete universal instruction. Water exposure, rubbing and gardening restrictions need the treating team’s specified duration; warn about worsening pain, redness or vision and give emergency access. A tall PED, including the quoted>600µm example, raises RPE-tear risk but does not predict a tear with certainty or justify automatically withholding indicated treatment. 1

07Do not treat every subretinal fluid pocket as AMD

Central serous chorioretinopathy (CSC/CSR/CCS) may occur with pachychoroid and SRF, often in younger adults, but age or stress is not diagnostic. Exogenous corticosteroids can provoke/worsen CSC: review exposure and coordinate any reduction rather than abruptly stopping essential systemic treatment. Observation or selected PDT depends on chronicity and findings; stress reduction alone is not a universal treatment. 1

Polypoidal choroidal vasculopathy (PCV) can cause serosanguineous PED; it is more frequent in some Asian populations but occurs across populations. The original double-hump phrase is not diagnostic by itself: OCT patterns prompt selected ICGA to assess aneurysmal lesions. Anti-VEGF and sometimes PDT are chosen by the actual lesion and response. Myopic MNV can respond with fewer injections than nAMD, but a single injection does not guarantee cure. 1

08Agree monitoring, rehabilitation and emergency access

Teach monocular Amsler self-checking and prompt reporting of new distortion without promising that a normal grid excludes activity. Adapt visits to stage, fellow-eye risk and treatment, and offer low-vision support when needed. Discuss cataract and visual expectations briefly; detailed IOL/blue-light-filter decisions belong to the separate cataract/maculopathy review. Suspected post-injection endophthalmitis needs urgent specialist treatment, often intravitreal antibiotics with vitrectomy selected by severity; it is not a wait-for-next-visit problem. 1

Agree monitoring, rehabilitation and emergency access
FindingDefinition/patternInvestigationManagementBoundary
DrusenDeposits below RPEFundus/OCTStage-based monitoring, selected AREDS2Different from intraretinal hard exudates
GAAtrophy; >175µm not universal, cRORA≥250µm with full criteriaFAF/OCTSupportive care; jurisdiction-specific complement options; PBM not routineGrowth endpoint is not restored vision
nAMDExudation/MNV1–3OCT/FA/OCT-AIndividual anti-VEGF, T&E or monitored PRNIRF prognosis does not make all SRF harmless
PCVSerosanguineous PEDOCT, selected ICGAAnti-VEGF±PDTDouble Hump alone not diagnostic
CSC/CSRSRF, pachychoroid contextOCT and differential work-upSelected observation/PDT, review steroidsDo not abruptly stop necessary systemic treatment
EndophthalmitisInflammation after injectionUrgent clinical assessmentIntravitreal antibiotics±vitrectomyPain, redness or visual loss: emergency
What are the main learning points?

Stage and activity guide management. Supplements are for selected risk groups; anti-VEGF treats active neovascular disease, and slowing atrophy growth is not the same as improving vision.

When is assessment urgent?

New distortion, a central scotoma or rapid visual loss needs prompt assessment. Pain, marked redness or visual loss after an injection is an emergency.

References and access status

  1. 1
    Immutable original export; general AMD lecture; examiner attribution unchecked

    Complete export read; original attribution and any recording/transcript or appointment not independently verified.

  2. 2
    Beckman clinical classification, Ferris et al.2013, PMID23332590

    Selected indexed classification abstract inspected16November2026; direct page extraction empty, full article/supplement not read.

  3. 3
    NEI AREDS/AREDS2 frequently asked questions

    Selected indication/formulation/relative-risk/smoking sections actually read16November2026; sponsor explanation, not independent full trial appraisal.

  4. 4
    CAM report3, Sadda et al.2018, PMID29103793

    Historical016 appraisal reused with its dated scope; no fresh full-article inspection.

  5. 5
    EMA Syfovre refusal re-examination, EMA/432931/2024

    Actual two-page extracted text read16November2026; negative opinion and benefit-risk reasons, not complete assessment or other products/current local labels.

  6. 6
    DOG/BVA/RG Photobiomodulation statement,4July2025

    All three extracted text pages including reference list read16November2026; cited trials/FDA dossier and newer results not independently read.

  7. 7
    DOG S1AMD risk/prevention, AWMF045-030,7September2026

    Official DOG listing and AWMF entry located16November2026; registry returned no extractable text, full recommendations pending.

Original lecture link